Corrected: BRIEF-Ionis Pharmaceuticals Q1 Revenue USD 246 Million Vs. IBES Estimate USD 195.6 Million
29/04/2026 12:00
Apr 29 (Reuters) - Ionis Pharmaceuticals Q1 operating expenses USD 364 million. Q1 operating income USD -118 million Q1 net income USD -93 million
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study